Division of Urology, School of Medicine, Università Politecnica delle Marche, Ancona.
Division of Pathology, School of Medicine, Università Politecnica delle Marche, Ancona.
Arch Ital Urol Androl. 2021 Mar 22;93(1):92-100. doi: 10.4081/aiua.2021.1.92.
Reasons why significant prostate cancer is still missed in early stage were investigated at the 22nd National SIEUN (Italian Society of integrated diagnostic in Urology, Andrology, Nephrology) congress took place from 30th November to 1st December 2020, in virtual modality. Even if multiparametric magnetic resonance (MR) has been introduced in the clinical practice several, limitations are emerging in patient with regular digital rectal examination (DRE) and serum prostate specific antigen (PSA) levels approaching the normal limits. The present paper summarizes highlights observed in those cases where significant prostate cancer may be missed by PSA or imaging and DRE. The issue of multidisciplinary interest had been subdivided and deepened under four main topics: biochemical, clinical, pathological and radiological point of view with a focus on PI-RADS 3 lesions.
在 2020 年 11 月 30 日至 12 月 1 日以虚拟模式举行的第 22 届全国 SIEUN（意大利泌尿科、男科和肾病学综合诊断学会）会议上，研究了为何仍会在早期阶段漏诊显著前列腺癌的原因。尽管多参数磁共振（MR）已在临床实践中得到应用，但对于常规直肠指检（DRE）和接近正常范围的血清前列腺特异性抗原（PSA）水平的患者，仍存在局限性。本文总结了在 PSA 或影像学和 DRE 可能漏诊显著前列腺癌的情况下观察到的要点。这一受到多学科关注的问题已分为四个主要专题进行深入探讨：从生化、临床、病理和放射学的角度，并重点关注 PI-RADS 3 病变。
